Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Gainesville, Florida + 6 more

Conditions: Chronic Conditions, Multiple, Chronic Conditions, Food Insecurity, Low-Income Population
Interventions: Grocery Support Monthly Program, Grocery Support One-Time Payment; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 6,975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gastrointestinal Neoplasms
Interventions: Endoscopic Submucosal Dissection, Endoscopic Mucosal Resection; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Glioma
Interventions: Questionnaires, Caregiver Assessment; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hydrocephalus
Interventions: MRE; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 45 Years to 95 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pancreatic Cancer, GastroEsophageal Cancer, Rectal Cancer, Head and Neck Cancer, Lymphoma
Interventions: Supportive Oncology Care at Home, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sleep, Well-Being (Psychological Flourishing)
Interventions: Equa, Coping Control; Behavioral
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Notre Dame, Indiana • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

Conditions: Cystic Fibrosis, Bone Loss, Muscle Loss
Interventions: Cftr Modulators; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: NavDx; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cardiovascular Disease, Alcohol Use Disorder, HIV Risk, Substance Use Disorders
Interventions: Navigation, compensation, and personalization; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 35 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Follicular Lymphoma (FL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy; Device · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parkinson Disease, Intestinal Bacteria Flora Disturbance, Dietary Modification
Interventions: Resistant maltodextrin, maltodextrin; Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsed and Refractory Multiple Myeloma
Interventions: anitocabtagene-autoleucel; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 40
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions: LY3410738, Venetoclax, Azacitidine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: Preterm Birth Complication
Interventions: SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program, SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program, Reference/ Standard of care; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Weeks to 33 Weeks
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Carcinoma
Interventions: Best Practice, Counseling, Electroencephalography, Neurofeedback, Questionnaire Administration; Other · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Non-Hodgkin
Interventions: Fludarabine, Cyclophosphamide, JCAR017; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 23
States / cities: Santa Monica, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Conditions: Stroke
Interventions: Group Lifestyle Balance, Usual Care; Behavioral · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cesarean Delivery
Interventions: Cesarean Risk Calculator; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Female only
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Ann Arbor, Michigan • Clinton Township, Michigan • Detroit, Michigan + 11 more

Conditions: Retinitis Pigmentosa
Interventions: Ophthalmic examinations, Mobility Test; Other
Lead sponsor: SparingVision; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Antibody-mediated Rejection
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • San Bernardino, California + 20 more

Search by objective public record fields.

LGMD R1 Natural History Study

Evaluating Covered California's Grocery Support Program

Monopolar Current Cutting Knife vs Bipolar RFA Knife

Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients

Magnetic Resonance Elastography in Hydrocephalus

Supportive Oncology Care At Home RCT

Cognitive Training for Student Sleep and Wellness

Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Serial Brain MRI in Hospitalized Preterm Infants

Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Group Lifestyle Balance™ for Individuals With Stroke (GLB-CVA)

IC-CS Risk: Patient Outcomes

Prospective Natural History Study of Retinitis Pigmentosa

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)